Radboud University Nijmegen

PDF hosted at the Radboud Repository of the Radboud University Nijmegen

The following full text is a publisher's version.

For additional information about this publication click this link. http://hdl.handle.net/2066/208810

Please be advised that this information was generated on 2020-09-09 and may be subject to change.





Original Article

Impact of dose adaptations following voriconazole therapeutic drug monitoring in pediatric patients

Vincent J. Lempers¹, Edmé Meuwese², Annelies M. Mavinkurve-Groothuis³, Stefanie Henriet⁴, Inge M. van der Sluis^{3,5}, Lidwien M. Hanff³, Adilia Warris⁶, Birgit C. P. Koch² and Roger J. Brüggemann^{1,7,*}

¹Radboud university medical center, Department of Pharmacy and Radboud Institute for Health Sciences, Nijmegen, The Netherlands, ²Erasmus Medical Center, Department of Pharmacy, Rotterdam, The Netherlands, ³Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands, ⁴Radboud university medical center, Department of Pediatric Infectious Diseases & Immunology, Nijmegen, The Netherlands, ⁵Erasmus Medical Center-Sophia Children's Hospital, Department of Pediatric Haematology-Oncology, Rotterdam, The Netherlands, ⁶MRC Centre for Medical Mycology, Aberdeen Fungal Group, Institute of Medical Sciences, University of Aberdeen, United Kingdom and ⁷Center of Expertise in Mycology Radboudumc/CWZ, Nijmegen, The Netherlands

*To whom correspondence should be addressed. Dr Roger JM Brüggemann, Department of Pharmacy 864, Radboud University Medical Center, Geert Grooteplein 10, 6525 GA Nijmegen, The Netherlands, E-mail: Roger.Bruggemann@radboudumc.nl

Received 12 November 2018; Revised 8 January 2019; Accepted 11 January 2019; Editorial Decision 9 January 2019

Abstract

Voriconazole is the mainstay of treatment for invasive aspergillosis in immunocompromised pediatric patients. Although Therapeutic Drug Monitoring (TDM) of voriconazole is recommended, it remains unknown if TDM-based dose adaptations result in target attainment. Patients <19 years from two pediatric hematologiconcology wards were retrospectively identified based on unexplained high voriconazole trough concentrations ($C_{min} > 6 \text{ mg/l}$). Patient demographics, clinical characteristics, treatment, voriconazole dosing information, voriconazole C_{min} before and after adjustment based on TDM were obtained. Twenty-one patients, median (range) age 7.0 (1.2-18.5) years, were identified in two centers. First C_{min} (3.1 mg/l [0.1-13.5]) was obtained after 3 days (1–27) of treatment. The median of all C_{min} (n = 485, median 11 per patient) was 2.16 mg/l (0.0 (undetectable)–28.0), with 24.1% of $C_{min} < 1$ mg/l, 48.9% 1–4 mg/l, 9.3% 4–6 mg/l, and 17.7% > 6 mg/l. Intrapatient variability was large (94.1% for IV, 88.5% for PO). Dose increases at C_{min} < 1 mg/l resulted in an increased C_{min} in 76.4%, with 60% between 1 and 4 mg/l. Dose decreases at $C_{min} > 6$ mg/l resulted in a decreased C_{min} in 80%, with 51% between 1 and 4 mg/l. Overall, in 45% of the cases (33 out of 55 and 12 out of 45) therapeutic targets were attained after dose adjustment. Fifty-five percent of initial C_{min} was outside the therapeutic target of 1–4 mg/l, with multiple dose adaptations required to achieve therapeutic concentrations. Only 60% and 51% of dose adaptations following sub- and supra-therapeutic C_{min} , respectively, did result in target attainment. Intensive and continuous TDM of voriconazole is a prerequisite for ensuring adequate exposure in pediatric patients.

Key words: voriconazole, therapeutic drug monitoring, pediatrics, azoles, pharmacokinetics.

Introduction

Voriconazole is a broad-spectrum triazole antifungal agent that has emerged as the preferred treatment of invasive aspergillosis in both children (≥ 2 years of age) and adults.^{1,2}

Increased voriconazole exposure has been associated with improved treatment outcome in adults, with suggested provisional cutoff points for voriconazole trough plasma concentrations (C_{min}) of 1–6 mg/l.^{3–6} An exposure-response relationship was also established for pediatric patients, in which a voriconazole

© The Author(s) 2019. Published by Oxford University Press on behalf of The International Society for Human and Animal Mycology. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

 $C_{min} > 1$ mg/l was associated with improved outcomes.^{7–11} Based on the relationship between voriconazole exposure and efficacy and the high inter- and intra-patient variability in pediatric patients,^{12–15} the importance of voriconazole therapeutic drug monitoring (TDM) in pediatric patients has been acknowledged.^{1,2,16,17} Although TDM-based dose adjustments are performed to optimize plasma concentrations, it remains unclear if these dose adaptations in pediatric patients correspond with target attainment.

We conducted a retrospective analysis in a cohort of pediatric oncology patients (both leukemia as well as lymphoma) with difficult to manage voriconazole concentrations and assessed the result of TDM-based dose adaptations on target attainment.

Methods

Study design and patients

This retrospective analysis was carried out in the pediatric hematology-oncology wards of two university hospitals in the Netherlands (Radboud university medical center, Nijmegen and Sophia Children's Hospital, Erasmus Medical Center, Rotterdam). From August 2007 to May 2014, the results from routinely performed TDM of voriconazole in both hospitalized and ambulant pediatric patients were evaluated. Patients < 19 years who received voriconazole orally (PO) or intravenously (IV) were included if more than one voriconazole C_{min} was determined, of which at least one concentration was >6 mg/l during treatment. Due to the retrospective nature of the study, written informed consent was deemed not necessary.

Data collection

Data were collected from the patients' medical records and included patient demographics (e.g., age, sex, body weight), voriconazole treatment data (e.g., route of administration, treatment duration, total daily dose, dose adjustments) and TDM data (e.g., plasma trough concentrations $[C_{min}]$, number of samples per patient, number of sub- and supra-therapeutic C_{min}). Concomitant medications with or without a known or suspected interaction with voriconazole exposure were reported.

Voriconazole dosing and dose adjustments

Initial dosing and administration of voriconazole was according to the Summary of Product Characteristics (SmPC) of voriconazole but could be increased or decreased based on clinical indications and TDM results. End of treatment was defined by successful clinical response, or by discontinuation due to a lack of clinical response, or adverse events. Consistent with institution guidelines during the study period, adequate voriconazole exposure was defined as C_{min} between 1 and 4 mg/l. If the patient showed no signs of hepatotoxicity (i.e., liver function tests no more than three times the upper limit of normal), C_{min} up to 6 mg/l were accepted. The 4 mg/l target concentration to prevent hepatotoxicity has been established in Asian patients particularly.^{18,19} In white people this relation has not been established with a clear cutoff value. Rather, an increase in drugs concentration, results in an increased chance of encountering hepatotoxicity.²⁰ In case of sanctuary infection sites or disseminated disease, the lower threshold was set to 2 mg/l (i.e., 2–4 mg/l or 2–6 mg/l). Target concentrations remain subject to debate but our target concentrations are in line with the recently published ESCMID guideline² and the ECIL guideline (available online via www.ecil-leukaemia.com).

In case of a sub- or supra-therapeutic voriconazole C_{min} (< 1 or > 6 mg/l), dose adjustments, assuming near-linear pharmacokinetics in children,¹⁴ to reach adequate C_{min} were subsequently made. A follow-up sample within 1 week was recommended. Dosing frequency was initially two times daily but could be increased to three times daily in an attempt to reach adequate voriconazole exposure.

Therapeutic Drug Monitoring

TDM was performed as standard of care, but frequency of sampling was dependent on individual decisions made for each patient. First, TDM sample was recommended at steady state concentrations of the drug, which is at least 2 days after initiation of voriconazole therapy or following dose adaptations. Only blood samples withdrawn within a 1-hour period prior to the next dose were included in the analysis to ascertain a trough concentration. Decisions on dose adaptations were made by experts in the field with knowledge on PK of voriconazole taking in mind the clinical condition of the patient.

Analytical assay

Voriconazole plasma concentrations were measured twice weekly using an in-house, validated ultra-performance liquid chromatography (HPLC) method with either a fluorescence or MSMS detection method (Waters).

Data analysis

A Spearman rank-order correlation was run to determine the relationship between voriconazole dose and C_{min} using SPSS 20.0 (SPSS Inc., Chicago, IL, USA). A *P*-value of <.05 was considered statistically significant. Intra-patient variability of voriconazole C_{min} was analyzed in patients who had at least three voriconazole C_{min} at similar doses and formulations.

Results

Patients

Twenty-one patients (8 male, 13 female) were eligible for analysis. Median (range) age at first dose was 7.0 years (1.2-18.5 years), of which 3 patients (14.3%) were <2 years, 11 (52.4%) between 2 and 12 years, and 7 (33.3%) between 12 and 19 years. Median (range) weight and body mass index were 21.9 kg (9.5–65) and 17.7 kg/m² (14–25.4), respectively (Table 1).

Voriconazole therapy

Patients received voriconazole therapy for a median (range) of 118 days (17–866; Table 1). The median total daily dose per kg (range) was 23.1 mg/kg (6.1–109.6). Initial voriconazole administration was IV in 15 (71.4%) and PO in 6 (28.6%) of patients. Five patients received voriconazole orally only, 2 only IV, and 14 received a combination of both. In four patients voriconazole was given TID at some time as part of their management strategy for a median (range) of 60 days (6–397) with a median total daily dose of 34.4 mg/kg (13.6–109.6). Median intra-individual variability of voriconazole dose was 94.1% during IV therapy (dose range: 12.2–16.0 mg/kg/day) and 88.5% during PO therapy (dose range: 10.5–44.1 mg/kg/day).

Therapeutic drug monitoring - initial Cmin

The first measurement of voriconazole C_{min} was performed at a median (range) of 3 days (1-27) after start of treatment, with a median (IQR) Cmin of 3.1 mg/l (1.34-7.0; Table 1). Upon first measurement, 11 out of 21 (52.4%) patients reached a Cmin between 1 and 6 mg/l (7 of these patients received voriconazole IV, 4 PO). Of the remaining 10 patients who had a voriconazole concentration <1 mg/l or >6 mg/l at first measurement, five out of nine patients (55.5%) required only 1 dose adaptation to achieve a C_{min} between 1 and 6 mg/l. Target concentrations in these nine patients were attained after a median (range) of 15 days (8-123). One patient was unable to achieve target values during the entire length of voriconazole therapy despite TDMbased dose adaptations. After the first suboptimal C_{min}, TDMbased dose adaptations were performed within a median of 2 days. A very weak positive correlation between voriconazole dose and initial Cmin was calculated, which was not statistically significant ($r^2 = 0.05, P = .82$).

Therapeutic drug monitoring – all C_{min}

In total, 485 samples were obtained with a median (range) concentration of 2.16 mg/l (undetectable -28; Table 1). Four concentrations (0.8%) were reported as below the lower limit of quantification. A median (range) of 11 samples (2–109) were drawn per patient, of which 117 (24.1%) were <1 mg/l, 237 (48.9%) between 1 and -4 mg/l, 45 (9.3%) between 4 and 6 mg/l and 86 (17.7%) >6 mg/l. An overview of all C_{min} per patient is shown in Figure 1. There was no significant correlation between voriconazole dose and all C_{min}, (r_s (485) = 0.02, P = .59). A C_{min} <1 mg/l was most frequently encountered in patients >12 years

receiving voriconazole IV, whereas patients 2–12 years suffered most frequently from $C_{min} > 6$ mg/l (Fig. 2).

Voriconazole dose adaptations

A total of 108 dose increases and 135 dose decreases were made, of which 50.9% when Cmin < 1, and 33.3% $C_{min} > 6$ (see Table 1). Out of a 117 cases with a $C_{min} < 1$ mg/l prompted a dose increase in 47.0% (n = 55) of occurrences, which resulted in an increased C_{min} at follow-up sampling in 76.4% (n = 42) of cases. In 60% (n = 33) of dose increases following a concentration of <1 mg/l, this led to a therapeutic C_{min} between 1 and 4 mg/l (median 1.7 mg/l). In these 33 cases, the total daily dose was increased from a median of 18.3 mg/kg/day to 22.7 mg/kg/day (24.0%).

Out of 86 cases with a C_{min} of >6 mg/l (median 8.29 mg/l) this prompted a dose decrease in 52.3% (n = 45) of cases, of which 80.0% (n = 36) resulted in a subsequent lower C_{min} at follow-up sampling. These dose decreases resulted in a C_{min} of <6 mg/l in 51.1% (n = 23) of cases and even led to concentrations between 1 and 4 mg/l (median 2.3 mg/l) in 26.7% (n = 12). In these 12 cases, the total daily dose was decreased from a median of 23.5 mg/kg/day to 16.8 mg/kg/day (39.9%).

Discussion

Here we present our experience with voriconazole TDM in a cohort of 21 pediatric patients with difficult to control voriconazole C_{min} , characterized by at least one $C_{min} > 6$ mg/l, enabling us to assess the result of TDM-based dose adaptations on voriconazole target attainment.

Overall, 18.5% of all doses adjustments made, based on TDM, resulted in target concentrations (1–4 mg/l). The vast majority (95.2%) of the patients in our study were able to achieve at least one therapeutic concentration (1–4 mg/l) after TDM-based dose adjustments. This is in a similar range of the reported value of 80% in a study from Bartelink et al., although voriconazole target values of 1–5 mg/l were used in this study.²¹

Of the total number of 485 voriconazole C_{min} , 24.1% was <1 mg/l, which is correlated with increased likelihood of treatment failure in children.⁷⁻⁹ In case of such a subtherapeutic C_{min} , voriconazole dose was increased in 47.0% of cases. Accordingly, 60% of dose increases resulted in the desired therapeutic C_{min} of 1–4 mg/l, with a median dose increase from 18.3 mg/kg/day to 22.7 mg/kg/day. Previous studies have reported that dose adjustments to median doses of 20–40 mg/kg/day were required to obtain therapeutic plasma concentrations of >1 mg/l.^{9,10,22} In addition, 17.7% of the total number of voriconazole C_{min} were >6 mg/l, which is regarded as a cutoff concentration is seen in pediatric patients.^{7,23,24} At these supratherapeutic concentrations, voriconazole dose was lowered in 52.3% of cases, resulting in a C_{min} between the target range of 1 and 4 mg/l in 26.7%

Table 1. Baseline characteristics (n = 21).

Demographics

Make (m [%1))8 (8.8.1)Franch (c (m [%1))36 (6.9.9)Are class (r)7.0 (1.2-18.5)Age class (r)11 (52.4)J 215 (n (%1))7.1 (3.3)J 215 (n (%1))7.1 (3.3)Race8 (8.7.7)White (n [%1])18 (8.7.7)Back (n [%1])1.1 (52.4)Actan (n [%1])1.1 (52.4)Actan (n [%1])1.1 (52.4)Mack (n [%1])1.1 (52.4)Actan (n [%1])1.1 (52.4)Median weight (kg (range))1.2 (9.965)Median weight (kg (range))1.2 (9.965)Median weight (kg (range))1.2 (9.965)Median weight (kg (range))1.2 (9.965)Intravenues administrations (%)1.2 (9.965)Intravenues administrations (%)1.2 (9.965)Intravenues administrations (%)1.2 (9.965)Median torol datip dose (m [mage])4.0 (1.0690.6)Intravenues administrations (%)1.2 (9.965)Median torol datip dose (m [mage])4.0 (1.0690.6)Median torol datip dose (m [mage])4.0 (1.0690.6)Median torol datip dose (m [mage])4.0 (1.0690.6)Median torol datip dose (m [mage])3.0 (1.370)Median torol datip dose (m [mage])3.0 (1.370)Median dose (m [mage])3.0 (1.370)Inti d C _{mack} down (m Cd2 C _{mack} (m [mage])3.0 (1.370)Inti d C _{mack} down (m Cd2 C _{mack} (m [mage])3.0 (1.370)Inti d C _{mack} down (m Cd2 C _{mack} (m [mage])3.0 (2.770)Median dose (m [m [m Gati])3.0 (2.770) <th>Sex</th> <th></th>	Sex	
Fermic (r [%])13 (i.1.9)Median age at for VC2P doe (r [range])7.01.1.2-18.5) $q \sim 2_1 (r [\%])3.14.31q \sim 2_1 (r [\%])3.14.3112-12 (r [\%])1.1 (52.4)12-13 (r [\%])1.1 (52.4)12-14 (r [\%])1.8 (85.7)Back (r [%])2.16.37Acc2.9.5Min (r [%])2.19.9.5-65Median weight (bg [range])2.19.95-65Median weight (bg [range])1.15.27Varicouzad kerapy (r [range])1.8 (85.7)Median weight (bg [range])1.15Median weight (bg [range])1.15Median days of VC2° (herapy (r [range])1.16Intravenous administrations (%)2.5.5Median total daily dose erap (r [range])4.19Median total daily dose erap (r [range])3.11.4-1.00.81The dosing (r [range])3.11.4-1.00.81Median total daily dose erap (r [range])4.19Median total daily dose erap (r [range])4.19Median total daily dose erap (r [range])3.11.4-1.00.81The dosing (r [range])3.11.4-1.00.81In data daily dose erap (r [range])3.11.4-1.00.81In data data dose erap (r [range])3.11.4-1.00.81In data dose erap (r [range])3.11.4-1.00.81In data dose erap (r [range])3.11.4-1.00.81In data $	Male $(n [\%])$	8 (38.1)
Median age at first VC2* dose (or [range])7.0 (1.3-18.3)9.4 ge doss (or [rs])3 (14.3)1.2-18 (or [rs])3 (14.3)2412 (or [rs])7 (33.3)Race7 (33.3)White (rs]%)1 (8 (85.7)Back (or [rs])1 (4.8)Asian (r[rs])1 (4.8)Median MM (rs]map()12.9 (9.5-45)Kace1 (4.8)Voriconazole therapy1 (4.8)Voriconazole therapy1 (1.7) (14-25.4)Voriconazole therapy1 (1.8) (7.8)Median MM (rs] (rs])1 (1.8) (7.8)Unitaria (rs] (rs])2.5Oral doministrations (%)2.5Oral doministrations (%)2.5Oral doministrations (%)2.5Oral doministrations (%)2.5Median total dialy dose (ng (rs]))4 (10)Median total dialy dose (ng (rs]))4 (10)Median total dialy dose (ng (rs]))4 (13.6)Median total dialy dose (ng (rs])3 (1.43-7.0)Initial Can-adge attents or therapy3 (0-27)Median total dialy dose durit (rs] (rs])3 (1.43-7.0)Initial Can-adge attents or therapy3 (0-27)Median total dialy dose durit (rs] (rs])3 (1.43-7.0)Initial Can-adge attents or therapy3 (0-27)Median total dialy dose durit (rs] (rs])3 (1.43-7.0)Initial Can-adge attents or therapy3 (0-27)Median total dialy dose durit (rs] (rs])3 (1.43-7.0)Initial Can-adge attents or therapy3 (0-27)Median total dialy dose durit (rs] (rs])3 (1.43-7.0) <td>Female (n [%])</td> <td>13 (61.9)</td>	Female (n [%])	13 (61.9)
Age class (pr) 3 (14.3) D=-2 (n [%]) 3 (14.3) 12-16 (n [%]) 7 (33.3) Rac 18 (85.7) Black (n [%]) 2 (9.5) Asin (n [%]) 2 (9.5) Asin (n [%]) 2 (9.5) Asin (n [%]) 14.83 Mician weight (lag (range)) 17.7 (14-25.4) Variconatole therapy 18 (17.6) Variconatole therapy 18 (17.6) Variconatole therapy 18 (17.6) Oral administrations (%) 25.5 Median total (dit) dose (ng (range)) 23.1 (6.1-10.6) Areal administrations (%) 25.5 Median total (dit) dose (ng (range)) 23.1 (6.1-10.6) Areal administrations (%) 4109 Median total (dit) dose (ng (range)) 30.47 (1.6) Areal administration (%) 31.1 (3.4-7.0) Median total (dit) dose (ng (range)) 30.42 (1.6) Median total (dit) dose (ng (range)) 30.41 (1.6) Theoreancet (ng momenting 31.1 (3.4-7.0) Median total (dit) dose (ng (range)) 30.42 (1.6) Ittadue an abora concentrat	Median age at first VCZ ^a dose (yr [range])	7.0 (1.2–18.5)
i = -2 (17 %[1)3 (14.3)212 (17 %[1)11 (52.4)L = 18 (17 %[1)7 (3.3.)Race1White (17 %[1)1 (8.5.7)Nack (17 %[1)1 (4.3)Astan (17 %[1)1 (4.3)Median Wit (kg/mapel)12.5Variout of %[1]118 (17-86)Invareous administrations (%)12.5Oral administrations (%)2.5.1Astan (17 %[1]118 (17-86)Invareous administrations (%)12.5Oral administrations (%)2.3.1 (6.1-09.6)Median Wit (kg/mapel)40 (120-2400)Median total duby does (ng rangel)40 (120-200)Median total duby does (ng rangel)30 (1-27)Median total duby does (ng rangel)30 (1-27)Median total duby does (ng rangel)30 (1-27)	Age class (yr)	
1-2 L2 [k [m]%]11 (2.4.)L2-18 (k [m]%]7 (3.3.)Rac18 (8.7.)White (n [m]%]18 (8.7.)Atan (n [m]%]1 (4.8.)Median weight (kg [range])1 (2.9.6.6.)Median weight (kg [range])1 (2.9.6.6.)Median weight (kg [range])1 (2.9.6.6.)Median days of VCZ ² therapy (n [range])118 (17-866.)Inravenous administrations (%)22.5.Median total day dose (mg [range])400 (120-2400)Median total day dose (mg [range])400 (120-2400)Median total day dose pet kg [range])23.1 (6.1-109.6)Patients on temporarily TDP dosing (mg/kg [range])34.4 (13.6-109.6)Median total day dose pet kg [range])34.4 (13.6-109.6)Patients on temporarily TDP dosing (mg/kg [range])34.4 (13.6-109.6)Median total day day courting (mg/kg [range])34.4 (13.6-109.6)TD dosing administrations (%) of total)11.1Therapeuti day montoring31.6 (1.3.4-7.0)Median days unit first measurement of VCZ ² Cum ⁶ (n [range])3.6 (3.3.4-7.0)Median plasma concentration of thera Cum ⁶ (mg [IQR ⁴))3.6 (3.6.1)Intravenous administration (%)4.6.4.1Intravenous administration (%)4.6.4.1Intravenous administration (%)4.6.2.1Intravenous administration (%)4.6.2.1Intravenous administration (%)4.6.2.1Intravenous administration (%)4.6.2.1Intravenous administration (%)4.6.2.1Intravenous administration (%)4.6.2.1Intravenous admini	0–<2 (<i>n</i> [%])	3 (14.3)
12-16 (n [%])7 (33.)Rac18 (85.7)Dark (n [%])18 (85.7)Dark (n [%])2 (2,5)Atam (n [%])14.8)Median KM (kg/ range)21.5 (5.5)Oriconazole therapy17.7 (14.25.6)Virconazole therapy18 (17.866)Virconazole therapy18 (17.866)Median KM (kg/ range)10.5 (7.5)Median KM (kg/ range)25.1 (7.5)Oriconazole therapy10.0 (7.5)Median total daily dose (ng (range))400 (120-2400)Median days of TDP' dosen (nrange)60 (6-397)Median days of TDP' dosen (nrange)60 (6-397)Median days daily dose during TD dosing (ng/kg [range])34 (13.6-109.8)Median days daily dose during TD dosing (ng/kg [range])34 (13.6-109.8)Intil Game dosen (nrange)60 (6-397)Median days dail patents)11.1Therapeutic drug monitoring42.5Median days dail first measurement of VC2* Came* (nrange])34 (13.6-109.8)Initial Came dose therapeutic range (% of all patents)42.5Initial Came dose therapeutic range (% of all patents)42.5Initial Came dose therapeutic range (% of all patents)42.5Initial Came dose therapeutic range (% of all patents)42.63.1 <td>2–<12 (<i>n</i> [%])</td> <td>11 (52.4)</td>	2–<12 (<i>n</i> [%])	11 (52.4)
Raceis start of the	12–18 (<i>n</i> [%])	7 (33.3)
White (n [%))18 (8.7.)Back (n [%))1 (4.8)Axian (n [%))1.19 (3-6.5)Median weight (kg (range))2.19 (3-6.5)Varicanzole therapy7.7 (14-25.4)Varicanzole therapy7.7 (14-25.4)Wacian SM (VCZ" therapy (n [range])118 (17-866)Intravenous administrations (%)2.5Oral administrations (%)400 (120-2400)Median toss of VCZ" therapy (n [range])400 (120-2400)Median toss of divid dose (ng (range))400 (120-2400)Median tosa (divid dose (ng (range))400 (120-2400)Median tosa (divid dose (ng (range))410 (19)Median tosa (divid dose (ng (range))410 (19)Median tosa (divid dose (ng (range))410 (19)Median tosa (divid dose (ng (range))34 (13.6-109.5)The dosing administrations (% of total)11.1Therapeutic drug monitoring31 (0-27)Median plasma concentent of VCZ" Cana ⁶ (n [range])3 (0-27)Median plasma concentent of VCZ" Cana ⁶ (n [range])3 (0-27)Median plasma concenter dire (% of all patients)11 (52.4)Intravenous administration (%)3 (75)Oral administration (%)3 (75)Oral administration (%)3 (75)Oral administration (%)4 (86.7)Intial Cana. booke therapeutic range (% of all patients)4 (86.7)Intial Cana. booke therapeutic range (% of all patients)4 (86.7)Oral administration (%)3 (75)Oral administration (%)4 (86.7)Oral administration (%)4 (86.7) <tr< td=""><td>Race</td><td></td></tr<>	Race	
Black (ng 1%)2 (2,5)Axian (ng 1%)1 (4,8)Median weight (kg [range])21,9 (9,5-63)Median BMI (kg/m² [range])17,7 (14-254)Voriconaccel kerapy12,5Median days of VCZ* therapy (n [range])118 (17-866)Intravenous administrations (%)22,5Oral administrations (%)23,5Median total daily dose (mg [range])400 (120-2400)Median total daily dose (mg [kg ng g])23,1 (6,1-109,6)Patients on temporarily TDP dosing (ng/kg [range])44 (13,6-109,6)Median total daily dose during TDD dosing (mg/kg [range])34,4 (13,6-109,6)TD dosing administrations (% of total)11.Therapeutic dam gromoitoring31 (1,3-4,70)Intial Cama adequate (% of all patients)31 (1,3-4,70)Intial Cama adequate (% of all patients)4 (19)Intravenous administration (%)7 (63,6)Oral administration (%)1 (25)Intravenous administration (%)3 (3,75)Oral administration (%)1 (25)Intravenous administration (%)1 (25)Intravenous administration (%)1 (25)Intravenous administration (%)3 (3,33)Oral administration (%)1 (25)Intravenous administration (%)1 (25)Intravenous administration (%)2 (3,33)	White (<i>n</i> [%])	18 (85.7)
Asian (r[%))1 (4.8)Median EMI (kg/m² [range])21.9 (9.5 - 6.5)Median EMI (kg/m² [range])17.7 (14-25.4)Voricoatcle therapy118 (17-86.6)Intravenous administrations (%)12.5Oral administrations (%)87.5Veria total dially dose (ng [range])400 (120-2400)Median days of VD² denarg)400 (120-2400)Median total dially dose (ng [range])41 (19)Median total dially dose (ng [range])60 (6-397)Median total dially dose (ng [range])34.4 (13.6-109.6)Di dosing administrations (%)41 (19)Median total dially dose (ng [range])34.4 (13.6-109.6)ID dosing administrations (%)4 (19)Median total dially dose (ng [range])31 (1-34-7.0)Indian days ontil first measurement of VCZ* Cama* (ng [ng [QR*]])31 (1.34-7.0)Initial Cama, adequate (% of all patients)7 (63.6)Oral administration (%)4 (19)Intravenous administration (%)3 (75.1)Oral administration (%)3 (25.1)Oral administration (%)4 (26.4)Intravenous administration (%)4 (26.7)Oral administration (%)11.7 (24.1)I-4 mg/l (ng [%)]22 (48.9)Ads patients4 (26.7)Oral administration (%)12 (27.7)Median durinistration (%)4 (26.7)Oral administration (%)12 (27.7)Median durinistration (%)3 (27.9)Oral administration (%)12 (28.9)I-4 mg/l (ng [%)]23 (48.9)I-4 mg/l (ng [%)] <t< td=""><td>Black (<i>n</i> [%])</td><td>2 (9.5)</td></t<>	Black (<i>n</i> [%])	2 (9.5)
Median weight (kg (range))21.9 (9.5-65)Nedian BMI (kg/m² (range))17.7 (14-23.4)Varicontack therapy11.8 (17-866)Intravenous administrations (%b)12.5Oral administrations (%b)87.5Median total daily dose (mg (range))400 (120-2400)Median total daily dose during TDb dosing (m [%b)400 (120-2400)Median total daily dose during TDb dosing (mg (range))400 (120-2400)Median total daily dose during TD dosing (mg/kg [range))41.1Therapeutic dang monitoring11.1Median days until first measurement of VCZ ² Cmm ⁶ (m [range])31.0.27)Median plasma concentration of first Cms ¹ (mg/l [IQR ⁴])31.0.47.0Initial Cmm ¹ adequate (% of all patients)11.62.40Intravenous administration (%)41.66.1Oral administration (%)41.66.1Oral administration (%)41.67.1Oral administration (%)41.66.7Oral administration (%)41.66.7Oral administration (%)41.67.1Unartownous administration (%)41.66.7Oral administration (%)41.66.7Oral administration (%)41.66.7Oral administration (%)41.66.7Oral administration (%)41.66.7Oral administr	Asian (<i>n</i> [%])	1 (4.8)
Median BAUI (kg/m² [range])17.7 (14-25.4)Voricontrole therapy118 (17-86.6)Welsin adays of VC2* therapy (n [range])18 (17-86.6)Intravenous administrations (%)87.5Median total daily dose (mg [range])400 (120-2400)Median total daily dose (mg [range])400 (120-2400)Median total daily dose (mg [range])41 (19)Median total daily dose (mg [range])60 (6-397)Median total daily dose (mg [range])34.4 (13.6-109.6)TiD dosing administrations (%) of total)11.1Therapeutic drag monitoring30 (0-27)Median total daily dose during TiD dosing (m/kg [range])3 (0-27)Median total daily dose during time (mg [range])3 (0-27)Median total daily dose during time (mg [range])3 (0-27)Median days of TiD ⁶ dosing (n range)3 (0-27)Median days during time (for gam concentration of first C _{min} (mg [range])3 (0-27)Median days during time (for gam concentration of first C _{min} (mg [range])3 (0-27)Intravenous daministration (%)7 (63.6)Oral administration (%)7 (63.6)Oral administration (%)1 (25.7)Intital C _{ma} abeve therapeutic range (% of all patients)6 (28.6)Intravenous administration (%)1 (25.7)Oral administration (%)2 (33.3)Total C _{min} 485Intital C _{ma} above therapeutic range (% of all patients)6 (28.6)Intravenous administration (%)11 (24.1)Intal C _{ma} above therapeutic range (% of all patients)1 (25.7)Median concent	Median weight (kg [range])	21.9 (9.5-65)
Vorconazole therapy 118 (17–866) Intravenous administrations (%) 12.5 Oral administrations (%) 87.5 Median total daily dose (mg (range)) 400 (120–2400) Median total daily dose (mg (range)) 41 (19) Patients on temporarily TD ⁶ dosing (m %) 4 (19) Median dust of TD ¹ dosing (m range) 60 (6–397) Median dust of TD ¹ dosing (m range) 34.4 (13.6–109.6) TD dosing administrations (% of total) 11.1 Therapeutic drage monitoring 7 Median days until first measurement of VCZ ⁴ C _{min} ⁶ (n [range]) 3 (0–27) Median days until first measurement of VCZ ⁴ C _{min} ⁶ (n [range]) 3 (0–27) Median days until first measurement of VCZ ⁴ C _{min} ⁶ (n [range]) 3 (0–27) Median days until first measurement of VCZ ⁴ C _{min} ⁶ (n [range]) 3 (0–27) Median days until first measurement of VCZ ⁴ C _{min} ⁶ (n [range]) 3 (0–27) Intravenous administration (%) 7 (63.6) Oral administration (%) 3 (0–27) Intravenous administration (%) 3 (75) Oral administration (%) 3 (75) Oral administration (%) 3 (75)	Median BMI (kg/m ² [range])	17.7 (14–25.4)
Median days of VČ2 ^k therapy (n [range])118 (17-866)Intravenous administrations (%)2.5Oral administrations (%)87.5Median total daily dose (mg [range])400 (120-2400)Median total daily dose (mg [range])40 (192-2400)Median total daily dose (mg [range])4 (19)Median total daily dosing (n [%))4 (19)Median total daily dosing (n [%))34 (13.6-109.6)TDD dosing administrations (%) of total)11.1Therapeutic drag monitoring3 (0-27)Median total daily dose during (mg/kg [range])3 (0-27)Median total daily dose during (mg/kg [range])3 (0-27)Initial C _{min} adequate (% of all patients)3 (0-27)Initial C _{min} adequate (% of all patients)1 (52.4)Intravenous administration (%)7 (63.6)Oral administration (%)3 (75.7)Oral administration (%) <td>Voriconazole therapy</td> <td></td>	Voriconazole therapy	
Intravenous administrations (%)12.5Oral administrations (%)87.5Oral administrations (%)87.5Median total daily dose (mg [range])400 (120-2400)Median total daily dose per kg (mg/kg [range])23.1 (6.1-109.6)Patients on temporarily TDb dosing (m [%)]4 (19)Median total daily dose during TDD dosing (mg/kg [range])34.4 (13.6-109.6)TDD dosing administrations (% of total)11.1Therapeutic drag monitoring11.1Median advas of finst C_mas ⁽ⁿ (mg/ [Rdg ¹])3.1 (1.3.4-7.0)Initial C _{min} adequate (% of all patients) ^e 11 (52.4)Intravenous administration (%)7 (63.6)Oral administration (%)7 (63.6)Oral administration (%)3 (75)Oral administration (%)3 (75)Oral administration (%)1 (25.1)Intravenous administration (%)3 (75)Oral administration (%)4 (86,7)Oral administration	Median days of VCZ ^a therapy $(n \text{ [range]})$	118 (17-866)
Oral administrations (%)87.5Median total daily dose (mg (mg/kg (range))400 (120–2400)Median total daily dose (mg/kg (range))2.3.1 (6.1–109.6)Patients on temporarily TDb dosing (mg/kg (range))4 (19)Median total daily dose (mg/kg mg/kg (range))60 (6–397)Median total daily dose (mg (mg/kg (range))3.4.4 (15.6–109.6)TD dosing administrations (% of total)11.1Therpetitic drug monitoring30–27)Median days util first measurement of VC2* C _{min} ⁶ (mg/l [IQR ⁴])3.1 (1.34–7.0)Initial C _{min} dequate (% of all patients)*11 (52.4)Intravenous administration (%)7 (63.6)Oral administration (%)3 (75)Oral administration (%)3 (75)Oral administration (%)1 (25)Initial C _{min} below therapeutic range (% of all patients)1 (25)Intravenous administration (%)2 (33.3)Oral administration (%)4 (67.7)Oral administration (%)1 (25)Intravenous administration (%)2 (33.3)Oral Administration (%)4 (67.7)Oral Administration (%)117 (24.1)1-4 mg/l (m[%))86 (17.7)Median concentration of all C _{min} (mg/l; range)23 (50.1)Dose adaptations (mg/l; fange)3 (60.7)Dose adaptations (mg/l; fa	Intravenous administrations (%)	12.5
Median total daily dose (mg [range])400 (120-2400)Median total daily dose per kg (mg/kg [range])23.1 (6.1-109.6)Patiens on temporarily TDP dosing (ng/kg)4 (19)Median days of TDP dosing (ng/kg [range])34.4 (13.6-109.6)TDD dosing administrations (% of total)1.1Therapeutic drug monitoring3.1 (6.2-70)Median days until first measurement of VCZ ² Cmm ⁶ (n [range])3.1 (1.34-7.0)Initial Cmin adequate (% of all patients) ⁶ 1.1 (32.4)Intravenous administration (%)7 (63.6)Oral administration (%)7 (63.6)Oral administration (%)4 (18.4)Intravenous administration (%)3 (75.1)Oral administration (%)1 (25.1)Intravenous administration (%)3 (75.1)Oral administration (%)1 (25.1)Intravenous administration (%)3 (75.1)Oral administration (%)2 (33.3)Total Cmm4 (86.7)Oral administration (%)2 (33.3)Total Cmm4 (86.7)Oral administration (%)2 (3.3)Total Cmm4 (8.9)Administration (%)2 (3.6)Oral administration (%)1 (72.4)Intravenous administration (%)2 (3.6)Intravenous administration (%)1 (72.4)Intravenous administration (%)2 (3.6)Oral administration (%)1 (72.4)Intravenous administration (%)3 (70.1)Oral administration (%)3 (70.1)Oral administration (%)3 (70.1)Oral administration (%)3 (70.1)<	Oral administrations (%)	87.5
Median total daily dose per kg (mg/kg [range])23.1 (6.1-109.6)Patients on temporarily TDb dosing (n [%])4 (19)Median days of TDb dosing (narge)34.4 (13.6-109.6)TDd dosing daministrations (% of total)11.1Therapeutic drug monitoring3 (0-27)Median days until first measurement of VCZ ³ C _{min} ⁶ (n [range])3 (0-27)Median dyss until first measurement of VCZ ³ C _{min} ⁶ (mg/l [IQR ⁴])3.1 (1.34-7.0)Intravenous administration (%)11 (52.4)Intravenous administration (%)7 (63.6)Oral administration (%)4 (19)Intravenous administration (%)4 (19)Intravenous administration (%)4 (28.6)Intravenous administration (%)4 (28.6)Intravenous administration (%)4 (28.6)Intravenous administration (%)1 (25.6)Intravenous administration (%)4 (28.6)Intravenous administration (%)1 (27.6)Intravenous administration (%)4 (28.6)Intravenous administration (%)4 (28.6)Intravenous administration (%)4 (28.6)Intravenous administration (%)4 (28.6)Intravenous administration (%)2 (28.6)Intravenous administration (%)4 (28.6)Intravenous administra	Median total daily dose (mg [range])	400 (120-2400)
Parients on temporarily TDb dosing (n (20)4 (19)Median total dualy dose during TDD dosing (mg/kg [range])60 (6-397)Median total dualy dose during TDD dosing (mg/kg [range])34 (13.6-109.6)TDD dosing administrations (% of total)11.1Therepeatic drug monitoring3 (0-27)Median total dualy dose during total of the transport3 (0-27)Median days until first measurement of VCZ ^A C _{min} ^e (m [range])3 (1.34-7.0)Initial C _{min} adequate (% of all patients) ^e 11 (52.4)Intravenous administration (%)7 (63.6)Oral administration (%)4 (16.4)Intravenous administration (%)3 (75)Oral administration (%)1 (25)Initial C _{min} below therapeutic range (% of all patients)6 (28.6)Intravenous administration (%)4 (66.7)Oral administration (%)2 (33.3)Total C _{min} 4 (50.7)Intravenous administration (%)11 (25.1)Intravenous administration (%)2 (33.3)Total C _{min} 4 (50.7)Intravenous administration (%)2 (33.3)Total C _{min} 4 (50.7)Veral administration (%)237 (48.9)4-6 mg/l (n [%))86 (17.7)Median constration of all C _{min} (mg/l; range)2.16 (0-28.0)Dose adaptations (m [%))55 (47)Resulted in increase in C _{min} 42 (56.4)Resulted in increase in C _{min} 45 (33.3)Ose decrease in C _{min} > 6 mg/l45 (33.3)Ose decrease at C _{min} > 6 mg/l45 (33.3)Resulted in increase in C _{min} <	Median total daily dose per kg (mg/kg [range])	23.1 (6.1–109.6)
Median days of TID ^b dosing (n range)60 (6-397)Median total daily dose during TID dosing (mg/kg [range]) 34.4 (13.6-109.6)TID dosing administrations (% of total) 11.1 Therapeutic drug monitoring 3 (0-27)Median days until first measurement of VC2 ^a C _{min} ^c (n [range]) 3 (0-27)Median days until first measurement of VC2 ^a C _{min} ^c (n [range]) 3 (0-27)Median plasma concentration of first C _{min} ^c (mg/l [IQR ^d]) 11 (52.4)Intital C _{min} adequate (% of all patients) 1 (52.4)Intital C _{min} denote the rapeutic range (% of all patients) 4 (19)Intravenous administration (%) 1 (25)Intital C _{min} below the rapeutic range (% of all patients) 6 (28.6)Intravenous administration (%) 2 (33.3)Oral administration (%) 2 (36.2)Doe increase (M [M [%]) 4 (66.7)Oral administration (%) 2 (36.2)Intal C _{min} (mg/l; range) 2 (7 (48.9) $4 - 1$ (17 (24.1) $1 - 2$ (4 (9.2)) $2 - 4$ (19/l) $4 - 4$ (19/l) $1 - 4$ mg/l (m [%]) 4 (60.7)Ose adaptations 4 (60.7)Dose adaptations 4 (60.7)Dose adaptations 1 (10 (10)Dose	Patients on temporarily TID ^b dosing $(n [\%])$	4 (19)
Median torul adily dose during TDD dosing (mg/kg [range]) 34.4 (13.6-109.6)TDD dosing administrations (% of total)11.1Therapeutic drag monitoringMedian days until first measurement of VCZ* C_{min}^c (n [range]) 3 (0-27)Median days until first measurement of VCZ* C_{min}^c (n [range]) 3 (0-27)Median days until first measurement of VCZ* C_{min}^c (n [range]) 3 (0-27)Median days until first measurement of VCZ* C_{min}^c (n [range]) 3 (0-27)Median days until first measurement of VCZ* C_{min}^c (n [range]) 3 (0-27)Median days administration (%) 11 (52.4)Intravenous administration (%) 4 (36.4)Intravenous administration (%) 4 (36.4)Intravenous administration (%) 1 (25)Intravenous administration (%) 1 (25)Intravenous administration (%) 2 (33.3)Total C_{min} 4 (66.7)Oral administration (%) 2 (33.3)Total C_{min} 4 (59.3) $4 - 6$ mg/l (n [%)) 237 (48.9) $4 - 6$ mg/l (n [%)) 237 (48.9) $4 - 6$ mg/l (n [%)) 237 (48.9) $4 - 6$ mg/l (n [%)) 243 (50.1)Dose adaptations of all C_{min} (mg/l; range) 243 (50.1)Dose increase (total) 108 Dose increase at $C_{min} - 1$ mg/l 33 (60)Dose docterase at $C_{min} - 6$ mg/l 45 (33.3)Resulted in increase in C_{min} 45 (33.3)Dose docterase at $C_{min} - 6$ mg/l 45 (33.3)Resulted in increase in $C_{min} - 6$ mg/l	Median days of TID ^b dosing (n range)	60 (6–397)
TID dosing administrations (% of total)11.1The appendix drug monitoring3 (0-27)Median days until first measurement of VC2 ^a Cmin ^e (n [range])3 (1-27)Median plasma concentration of first Cmig(mgl [IQR ^d])3.1 (1.34-7.0)Initial Cmin adequate (% of all patients) ^e 11 (52.4)Intravenous administration (%)7 (63.6)Oral administration (%)4 (36.4)Initial Cmin below therapeutic range (% of all patients)4 (36.4)Initial Cmin below therapeutic range (% of all patients)6 (28.6)Intravenous administration (%)3 (75)Oral administration (%)6 (28.6)Intravenous administration (%)2 (33.3)Oral administration (%)4 (66.7)Oral administration (%)2 (33.3)Oral administration (%)2 (33.3)Oral administration (%)2 (35.6)Intravenous administration (%)2 (35.6)Oral administration (%)117 (24.1)1-4 mg/l (n [%))8 (17.7)Median concentration of all Cmin (mg/l; range)2.16 (0-28.0)Dose adaptations243 (50.1)Dose increase (total)108Dose increase at Cmin < 1 mg/l (n [%])	Median total daily dose during TID dosing (mg/kg [range])	34.4 (13.6–109.6)
Therapeutic drug monitoringMedian days until first measurement of VCZ* C_{min}^c (n [range]) 3 (0–27)Median plasma concentration of first C_{min}^c (mgl [IQR ^d]) 3.1 (1.34–7.0)Initial C_{ma} adequate (% of all patients) 11 (52.4)Intravenous administration (%)7 (63.6)Oral administration (%)4 (36.4)Initial C_{ma} below therapeutic range (% of all patients)4 (19)Intravenous administration (%)3 (75)Oral administration (%)3 (75)Oral administration (%)6 (28.6)Intravenous administration (%)2 (33.3)Total C_{min} 485Cal mgl (n [%))117 (24.1)1-4 mgl (n [%))237 (48.5)4-6 mgl (n [%))45 (9.3)6 of mgl (n [%))2.16 (0–28.0)Dose adaptations of all C_{min} (mgl); range)2.16 (0–28.0)Dose adaptations of all C_{min} (mgl); range)55 (47)Resulted in increase in C_{min} 42 (56.4)Increase at $C_{min} < 1 mgl (n [%))$ 35 (47)Resulted in increase in C_{min} 45 (9.3)Dose adaptations of all C_{min} (mgl, range)2.16 (0–28.0)Dose adaptations of all C_{min} (mgl, range)55 (47)Resulted in increase in C_{min} 45 (3.3)Resulted in incr	TID dosing administrations (% of total)	11.1
Intrapende larg monitong 3 (0-27) Median days until first measurement of VCZ ⁴ C _{min} ⁶ (ng/ng[lQR ^d]) 3.1 (1.34–7.0) Initial C _{min} adequate (% of all patients) ⁶ 11 (52.4) Intravenous administration (%) 7 (63.6) Oral administration (%) 4 (36.4) Initial C _{min} below therapeutic range (% of all patients) 4 (19) Intravenous administration (%) 3 (75) Oral administration (%) 1 (25) Initial C _{min} below therapeutic range (% of all patients) 6 (28.6) Intravenous administration (%) 2 (33.3) Oral administration (%) 4 (66.7) Oral administration (%) 4 (66.7) Oral administration (%) 2 (33.3) Total C _{min} 485 1 mg/l (n [%)] 117 (24.1) 1-4 mg/l (n [%]) 45 (9.3) > 6 mg/l (n [%]) 86 (17.7) Median concentration of all C _{min} (mg/l; range) 263 (50.1) Dose adaptations 243 (50.1) Dose increase (total) 108 Dose increase at C _{min} < 1 mg/l (n [%))	Thereation drug monitoring	
Archan days min this inclustration (Gr CZ Come (n (range)) $3, (1, 13-7, 0)$ Median plasma concentration of first Come ⁶ (mg/l [IQR ^d]) $11 (52, 4)$ Intravenous administration (%) 7 (63, 6) Oral administration (%) 4 (36, 4) Initial C _{min} adequate (% of all patients) 4 (19) Intravenous administration (%) 3 (75) Oral administration (%) 1 (25) Initial C _{min} above therapeutic range (% of all patients) 6 (28, 6) Intravenous administration (%) 2 (33, 3) Oral administration (%) 2 (33, 3) Total C _{min} 485 <1 mg/l (n [%))	Interpretation days until first measurement of $VC7^{a}C \rightarrow c'$ (a [range])	3 (0, 27)
Anction parametric for all patients) 11 (13-47-36) Initial C_{min} adequate (% of all patients) 11 (52,4) Intravenous administration (%) 7 (63.6) Oral administration (%) 4 (36.4) Initial C_{min} below therapeutic range (% of all patients) 4 (19) Intravenous administration (%) 1 (25) Oral administration (%) 1 (25) Intravenous administration (%) 2 (33.3) Oral administration (%) 2 (33.3) Total C_{min} 485 <1 mg/l (n [%])	Median plasma concentration of first $C \rightarrow c (mg/l [IORd])$	3(0-27) 3 1 (1 34 7 0)
Intracember dequart (%) of an parents) If (6.2-1) Intracember dequart (%) of an parents) 7 (63.6) Oral administration (%) 4 (36.4) Intracember administration (%) 3 (75) Oral administration (%) 1 (25) Initial C_{min} below therapeutic range (% of all patients) 6 (28.6) Intravenous administration (%) 2 (33.3) Oral administration (%) 2 (74.8) Administration (%) 2 (76.4) Path (n [%]) 86 (17.7) Aded adptations 2.16 (0-28.0) Dose daptations 2.16 (0-28.0) Dose increase (tral) 108 Dose increase at $C_{min} < 1 mg/l (n [%])$ 25 (51.7) Resulted in increase in $C_{min} < 1 mg/l (n [%])$ 33 (60) Dose increase at $C_{min} < 1 mg/l (n [%])$ 33 (60) Dose increase at $C_{min} < 1 mg/l (n [%])$ 33 (60)	Initial C_{\pm} adequate (% of all patients) ^e	(1.57 - 7.0)
Intravenous administration (%) 4 (36.4) Initial C_{min} below therapeutic range (% of all patients) 4 (19) Intravenous administration (%) 3 (75) Oral administration (%) 1 (25) Initial C_{min} above therapeutic range (% of all patients) 6 (28.6) Intravenous administration (%) 2 (33.3) Oral administration (%) 2 (33.3) Total C_{min} 485 <1 mg/l (n [%)]	Intravenous administration (%)	7 (63.6)
Orthologies1 (30.1)Initial C_{min} below therapeutic range (% of all patients)3 (75)Intravenous administration (%)1 (25)Intraderous administration (%)6 (28.6)Intravenous administration (%)2 (33.3)Oral administration (%)2 (33.3)Total C_{min} 485<1 mg/l (n [%])	Oral administration (%)	4 (36 4)
Intra equit 0 condition (%) 3 (75) Oral administration (%) 1 (25) Initial C_{min} above therapeutic range (% of all patients) 6 (28.6) Intravenous administration (%) 2 (33.3) Oral administration (%) 117 (24.1) I administration (%) 117 (24.1) 1-4 mg/l (n [%)) 117 (24.1) 1-4 mg/l (n [%)) 237 (48.9) 4-6 mg/l (n [%)) 237 (48.9) 4-6 mg/l (n [%)) 86 (17.7) Median concentration of all C_{min} (mg/l; range) 26 (30.1) Dose adaptations 243 (50.1) Dose increases (total) 108 Dose increase at $C_{min} < 1 mg/l (n [%))$ 55 (47) Resulted in increase in C_{min} 45 (33.3) Ose decrease (total) 135 Dose decrease at $C_{min} > 6 mg/l$ 33 (60) Dose decrease in $C_{min} > 6 mg/l$ 33 (60,0) Resulted in decrease in $C_{min} > 6 mg/l$ 35 (33.3) Resulted in decrease in $C_{min} > 6 mg/l$ 36 (80.0) Resulted in $C_{min} < 6 mg/l$ 23 (51.1) Resulted in $C_{min} < 6 mg/l$ 23 (51.1) Resulted in $C_{min} < 6 mg/l$ 23 (51.1)	Initial C_{\pm} below the appendix range (% of all patients)	4 (19)
Initial Chain Matriation (%) 5 (3) Oral administration (%) 1 (25) Initial Cmin above therapeutic range (% of all patients) 6 (28.6) Intravenous administration (%) 2 (33.3) Oral administration (%) 2 (33.3) Total Cmin 4 (66.7) Oral administration (%) 117 (24.1) 1-4 mg/l (n [%)) 237 (48.9) 4-6 mg/l (n [%)) 45 (9.3) > 6 mg/l (n [%)) 45 (9.3) > 6 mg/l (n [%)) 86 (17.7) Median concentration of all Cmin (mg/l; range) 2.16 (0-28.0) Dose adaptations 2.143 (50.1) Dose adaptations 108 Dose increases (total) 108 Dose increases at Cmin < 1 mg/l (n [%])	Intravenous administration (%)	3 (75)
Initial Cmin abund 100 (0) $1 (2.5)$ Initial Cmin above therapeutic range (% of all patients) $6 (28.6)$ Intravenous administration (%) $2 (33.3)$ Oral administration (%) $2 (33.3)$ Total C _{min} 485 <1 mg/ (n [%])	Oral administration (%)	1 (25)
Intravenue sem6 (500)Intravenue administration (%)2 (33.3)Total C_{min} 485<1 mg/l (n [%])	Initial Constant administration (70)	6 (28 6)
Intractions definition (%)1 (00.7)Oral administration (%)2 (33.3)Total C_{min} 485<1 mg/l (n [%])	Intravenous administration (%)	4 (66 7)
Total Cmin12 (50.5)Total Cmin485<1 mg/l (n [%])	Oral administration (%)	2 (33 3)
Note of the off107 $< 1 \mod n (n [\%])$ 117 (24.1) $1 - 4 \mod l (n [\%])$ 237 (48.9) $4 - 6 \mod l (n [\%])$ 45 (9.3)> 6 \mod l (n [\%])86 (17.7)Median concentration of all C_{\min} (mg/l; range)2.16 (0-28.0)Dose adaptationsDose adaptationsDose adaptations (n [%])243 (50.1)Dose increases (total)108Dose increases (total)55 (47)Resulted in increase in C_{\min} 42 (76.4)Resulted in $C_{\min} 1 - 4 \mod l$ 33 (60)Dose decrease (total)135Dose decrease in C_{\min} 45 (33.3)Resulted in decrease in C_{\min} 36 (80.0)Resulted in $C_{\min} < 6 \mod l$ 23 (51.1)Resulted in $C_{\min} 1 - 4 \mod l$ 23 (51.1)Resulted in $C_{\min} - 4 \mod l$ 23 (51.1)	Total C	485
IntegrationIntegration $1-4 \text{mg/l} (n [\%])$ 237 (48.9) $4-6 \text{mg/l} (n [\%])$ 45 (9.3) $>6 \text{mg/l} (n [\%])$ 86 (17.7)Median concentration of all C _{min} (mg/l; range)2.16 (0-28.0)Dose adaptations243 (50.1)Dose increases (total)108Dose increase at C _{min} < 1 mg/l (n $[\%]$)55 (47)Resulted in increase in C _{min} 42 (76.4)Resulted in C _{min} 1-4 mg/l33 (60)Dose decrease (total)135Dose decrease at C _{min} > 6 mg/l45 (33.3)Resulted in decrease in C _{min} 36 (80.0)Resulted in C _{min} < 6 mg/l	< 1 mg/ (n [%])	117 (24 1)
$4-6 \text{ mg/l} (n [\%])$ $45 (9.3)$ $>6 \text{ mg/l} (n [\%])$ $86 (17.7)$ Median concentration of all C _{min} (mg/l; range) $2.16 (0-28.0)$ Dose adaptations $243 (50.1)$ Dose adaptations 108 Dose increases (total) 108 Dose increase at $C_{min} < 1 \text{ mg/l} (n [\%])$ $55 (47)$ Resulted in increase in C_{min} $42 (76.4)$ Resulted in $C_{min} 1-4 \text{ mg/l}$ $33 (60)$ Dose decrease (total) 135 Dose decrease in $C_{min} > 6 \text{ mg/l}$ $45 (33.3)$ Resulted in decrease in C_{min} $36 (80.0)$ Resulted in $C_{min} < 6 \text{ mg/l}$ $23 (51.1)$ Resulted in $C_{min} 1-4 \text{ mg/l}$ $23 (51.1)$	1-4 mg/l (n [%])	237 (48.9)
$1 \circ \ln gl(n [nd])$ $1 \circ \log (n [nd])$ > $6 \circ ngl(n [nd])$ $8 \circ (17.7)$ Median concentration of all C_{min} (mg/l; range) $2.16 (0-28.0)$ Dose adaptations $243 (50.1)$ Dose adaptations ($n [nd])$ $243 (50.1)$ Dose increases (total) 108 Dose increase at $C_{min} < 1 mg/l (n [nd])$ $55 (47)$ Resulted in increase in C_{min} $42 (76.4)$ Resulted in $C_{min} 1-4 mg/l$ $33 (60)$ Dose decrease (total) 135 Dose decrease in $C_{min} < 6 mg/l$ $45 (33.3)$ Resulted in decrease in C_{min} $36 (80.0)$ Resulted in $C_{min} < 6 mg/l$ $23 (51.1)$ Resulted in $C_{min} 1-4 mg/l$ $23 (51.1)$ Resulted in $C_{min} 1-4 mg/l$ $21 (26.7)$	4-6 mg/l (n [%])	45 (9 3)
Median concentration of all C_{min} (mg/l; range) 2.16 (0-28.0) Dose adaptations 243 (50.1) Dose adaptations (n [%]) 243 (50.1) Dose increases (total) 108 Dose increase at $C_{min} < 1 mg/l (n [\%])$ 55 (47) Resulted in increase in C_{min} 42 (76.4) Resulted in $C_{min} 1-4 mg/l$ 33 (60) Dose decrease (total) 135 Dose decrease at $C_{min} > 6 mg/l$ 45 (33.3) Resulted in decrease in C_{min} 36 (80.0) Resulted in $C_{min} < 6 mg/l$ 23 (51.1) Resulted in $C_{min} 1-4 mg/l$ 23 (51.1)	> 6 mg/(n[%])	86 (17 7)
Internal contentation of all online (alg.), failing (alg.)Internal contentation of all of alg.)Dose adaptations243 (50.1)Dose increases (total)108Dose increase at $C_{min} < 1 mg/l (n [\%])$ 55 (47)Resulted in increase in C_{min} 42 (76.4)Resulted in $C_{min} 1-4 mg/l$ 33 (60)Dose decrease (total)135Dose decrease at $C_{min} > 6 mg/l$ 45 (33.3)Resulted in decrease in C_{min} 36 (80.0)Resulted in $C_{min} < 6 mg/l$ 23 (51.1)Resulted in $C_{min} 1-4 mg/l$ 12 (26.7)	Median concentration of all C _{min} (mg/l: range)	2.16(0-28.0)
Dose adaptations243 (50.1)Dose increases (total)108Dose increase at $C_{min} < 1 \text{ mg/l} (n [\%])$ 55 (47)Resulted in increase in C_{min} 42 (76.4)Resulted in $C_{min} 1-4 \text{ mg/l}$ 33 (60)Dose decrease (total)135Dose decrease at $C_{min} > 6 \text{ mg/l}$ 45 (33.3)Resulted in $C_{min} < 6 \text{ mg/l}$ 36 (80.0)Resulted in $C_{min} - 4 \text{ mg/l}$ 23 (51.1)Resulted in $C_{min} 1-4 \text{ mg/l}$ 23 (51.1)		
Dose adaptations $(n [\%])$ 243 (50.1)Dose increases (total)108Dose increase at $C_{min} < 1 mg/l (n [\%])$ 55 (47)Resulted in increase in C_{min} 42 (76.4)Resulted in $C_{min} 1-4 mg/l$ 33 (60)Dose decrease (total)135Dose decrease at $C_{min} > 6 mg/l$ 45 (33.3)Resulted in decrease in C_{min} 36 (80.0)Resulted in $C_{min} < 6 mg/l$ 23 (51.1)Resulted in $C_{min} 1-4 mg/l$ 12 (26.7)	Dose adaptations	
Dose increases (total) 108 Dose increase at $C_{min} < 1 \text{ mg/l} (n [\%])$ 55 (47) Resulted in increase in C_{min} 42 (76.4) Resulted in $C_{min} 1-4 \text{ mg/l}$ 33 (60) Dose decrease (total) 135 Dose decrease at $C_{min} > 6 \text{ mg/l}$ 45 (33.3) Resulted in decrease in C_{min} 36 (80.0) Resulted in $C_{min} < 6 \text{ mg/l}$ 23 (51.1) Resulted in $C_{min} 1-4 \text{ mg/l}$ 12 (26.7)	Dose adaptations ($n [\%]$)	243 (50.1)
Dose increase at $C_{min} < 1 \text{ mg/l} (n [\%])$ 55 (47) Resulted in increase in C_{min} 42 (76.4) Resulted in $C_{min} 1-4 \text{ mg/l}$ 33 (60) Dose decrease (total) 135 Dose decrease at $C_{min} > 6 \text{ mg/l}$ 45 (33.3) Resulted in decrease in C_{min} 36 (80.0) Resulted in $C_{min} < 6 \text{ mg/l}$ 23 (51.1) Resulted in $C_{min} 1-4 \text{ mg/l}$ 12 (26.7)	Dose increases (total)	108
Resulted in increase in C_{min} 42 (76.4)Resulted in C_{min} 1–4 mg/l33 (60)Dose decrease (total)135Dose decrease at $C_{min} > 6$ mg/l45 (33.3)Resulted in decrease in C_{min} 36 (80.0)Resulted in $C_{min} < 6$ mg/l23 (51.1)Resulted in C_{min} 1–4 mg/l12 (26.7)	Dose increase at $C_{\min} < 1 \text{ mg/l} (n [\%])$	55 (47)
Resulted in C_{min} 1–4 mg/l 33 (60) Dose decrease (total) 135 Dose decrease at $C_{min} > 6$ mg/l 45 (33.3) Resulted in decrease in C_{min} 36 (80.0) Resulted in $C_{min} < 6$ mg/l 23 (51.1) Resulted in C_{min} 1–4 mg/l 12 (26.7)	Resulted in increase in C _{min}	42 (76.4)
Dose decrease (total)135Dose decrease at $C_{min} > 6 \text{ mg/l}$ 45 (33.3)Resulted in decrease in C_{min} 36 (80.0)Resulted in $C_{min} < 6 \text{ mg/l}$ 23 (51.1)Resulted in $C_{min} 1-4 \text{ mg/l}$ 12 (26.7)	Resulted in C _{min} 1–4 mg/l	33 (60)
Dose decrease at $C_{min} > 6 \text{ mg/l}$ 45 (33.3)Resulted in decrease in C_{min} 36 (80.0)Resulted in $C_{min} < 6 \text{ mg/l}$ 23 (51.1)Resulted in C_{min} 1–4 mg/l12 (26.7)	Dose decrease (total)	135
Resulted in decrease in C_{min} 36 (80.0)Resulted in $C_{min} < 6 \text{ mg/l}$ 23 (51.1)Resulted in C_{min} 1–4 mg/l12 (26.7)	Dose decrease at $C_{min} > 6 \text{ mg/l}$	45 (33.3)
Resulted in $C_{min} < 6 \text{ mg/l}$ 23 (51.1) Resulted in C_{min} 1–4 mg/l 12 (26.7)	Resulted in decrease in C _{min}	36 (80.0)
Resulted in C _{min} 1–4 mg/l 12 (26.7)	Resulted in $C_{min} < 6 \text{ mg/l}$	23 (51.1)
	Resulted in C _{min} 1–4 mg/l	12 (26.7)

 $^{a}VCZ = voriconazole$. $^{b}TID =$ three times per day. $^{c}C_{min} =$ trough concentration. $^{d}IQR =$ Interquartile range. $^{e}Adequate$ therapeutic range of voriconazole C_{min} is considered to be between 1 and 4 mg/l (1–6 if adequate liver function tests). Subtherapeutic C_{min} at <1 mg/l, supratherapeutic C_{min} at <6 mg/l.



Figure 1. Overview of all voriconazole trough concentrations at varying doses (n = 485) in 21 patients.

of cases (decreasing the median dose from 23.5 mg/kg/day to 16.8 mg/kg/day).

Age is one of the most important factors influencing voriconazole plasma exposure, as voriconazole clearance has been shown to be much higher in children under the age of 12, and oral bioavailability of voriconazole is lower in children (65%), compared to adults (96%).^{14,25} As a result, several studies reported similar voriconazole exposure in children (<12 years) compared to adults with IV doses of 7-9 mg/kg BID.^{13,14,25} This prompted higher dosing regimens in children compared to adults. Although voriconazole has been reported to display near-linear pharmacokinetics in children receiving multiple doses of 3 mg/kg and 4 mg/kg BID IV¹⁵ (i.e., doses that have been found effective in clinical trials with adults), increasing evidence suggests saturated (nonlinear) pharmacokinetic behavior is observed in children receiving doses higher than 7 mg/kg BID. We found no predictable relationship between dose and C_{min} (Fig. 1,2), and it remains unclear from current literature if such a relationship exists. Given the high maintenance doses in our study (median 23.1 mg/kg/day), this could explain the absence of a dose/concentration relationship. Another explanation could be found in the high intra-subject variability in voriconazole Cmin

both after IV and PO dosing (Fig. 1), which is consistent with other pediatric studies.^{12-14,25}

Due to the retrospective nature of this study, laboratory data on the majority of our patients were limited and often obtained only on the day of voriconazole TDM. In addition, markers for hepatic function were not always investigated in parallel. It was therefore not possible to draw any conclusions on the yet unclear relationship between voriconazole C_{min} and hepatotoxicity in pediatric patients. Because the focus of our study on the relationship between dose adjustments and target attainment, we did not monitor for voriconazole-related adverse events (e.g., neurological adverse events, phototoxic skin reactions, and potentially proarrhythmic conditions) in relation to dose or exposure.

Despite rapid dose adaptations after the first subtherapeutic C_{min} in our study (median of 2 days), a median of 15 days was required to obtain an adequate C_{min} , increasing the risk of inadequately treated fungal infections and unfavourable outcome. Of all dose adaptations following both sub –and supratherapeutic C_{min} , only 45% resulted in a therapeutic C_{min} between 1 and 4 mg/l at the following concentration measurement. If we would stretch the therapeutic targets to 1–6 mg/l (assuming all C_{min} between 4 and 6 mg/l were acceptable based on adequate liver



Aq	e	q	ro	u	p
	-				-

		C _{min} (% of total)			
Age group	Formulation	< 1 mg/L (n)	1 - 4 mg/L (n)	>4 - 6 mg/L (n)	> 6 mg/L (n)
< 2 years	IV	28.1 (9)	56.3 (18)	6.3 (2)	9.4 (3)
	РО	28.1 (9)	37.5 (12)	12.5 (4)	21.9 (7)
2-12 years	IV	23.8 (10)	35.7 (15)	9.5 (4)	31.0 (13)
	РО	21.1 (52)	54.5 (134)	8.5 (21)	15.9 (39)
>12 years	IV	41.7 (5)	50.0 (6)	0.0 (0)	8.3 (1)
	PO	26.3 (32)	43.0 (52)	11.6 (14)	19.0 (23)

		Median dose administered (mg/kg/day)			
Age group	Formulation	< 1 mg/L	1 - 4 mg/L	>4 - 6 mg/L	> 6 mg/L
< 2 years	IV	12.2	11.9	N/A	12.9
	РО	12.2	12.3	22.0	12.6
2-12 years	IV	17.1	24.5	15.7	57.9
	РО	24.0	25.9	22.9	28.2
>12 years	IV	10.0	11.1	N/A	N/A
	РО	18.4	15.7	11.0	10.4

Figure 2. Voriconazole C_{min} distribution (%) per formulation per age group. C_{min}: trough concentration. IV: intravenous. PO: Oral.

function tests), 56% of dose adaptations would result in target attainment.

Dose adaptations were done by experts with expertise in the field of antifungal pharmacology but without a nomogram. For purposes of personalized dosing, there is an urgent need to implement advanced pharmacometric models with "clinician-proof" software, that can take into account all important determinants for treatment response. Nowadays, model-informed precision dosing (MIPD) can be deployed as a technique to forecast dosing in the individual. Programs such as InsightRx, DoseMe and Best Dose fulfil this need and are being tested in the clinic. To take advantage of this approach, solid pharmacokinetic models must be available to be used in MIPD. Here we can still gain knowledge for this specific drug and the current population as the unexplained inter-individual variability in published models remains very large. Before implementation in routine patient management, these models must be prospectively validated to demonstrate its value. In addition, the software must comply to relevant legislation (e.g., CE label in Europe) when deployed outside of a research scope. Nevertheless, this is the way forward taking advantage of a platform for individualized treatment with visual feedback.

Given the difficulty of target attainment despite dose adaptations, together with the prior observed relationship between voriconazole exposure and efficacy and adverse events and the large inter- and intrapatient variability in children, this study underscores the indispensable need for voriconazole TDM in severely immunocompromised pediatric patients early in the course of treatment with multiple follow-up samples during therapy when aiming to optimize treatment outcomes.

Acknowledgments

This manuscript was derived from chapter 9 of the PhD thesis by Vincent Lempers done at Radboudumc, which can be found at: https://repository.ubn.ru.nl/bitstream/handle/2066/157075/157075.pdf? sequence=1.

A.W. is supported by the Wellcome Trust Strategic Award (grant 097377), and the MRC Centre for Medical Mycology (grant MR/N006364/1) at the University of Aberdeen.

Funding

This study was funded by the Department of Pharmacy Radboudumc.

Declaration of interest

V.J.C. is now an employee of Gilead. At the time of research he was employed by Radboudumc.

All other authors have no conflicts of interest with regards to this work.

Outside this work, R.J.B. has served as a consultant to Astellas Pharma, Inc., F2G, Gilead Sciences, Merck Sharp & Dohme Corp., and Pfizer, Inc., and has received unrestricted and research grants from Astellas Pharma, Inc., Gilead Sciences, Merck Sharp & Dohme Corp., and Pfizer, Inc. All contracts were through Radboudumc, and all payments were invoiced by Radboudumc.

References

- Patterson TF, Thompson GR, 3rd, Denning DW et al. Practice guidelines for the diagnosis and management of aspergillosis: 2016 Update by the Infectious Diseases Society of America. *Clin Infect Dis.* 2016; 63: e1–e60.
- Ullmann AJ, Aguado JM, Arikan-Akdagli S et al. Diagnosis and management of *Aspergillus* diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline. *Clin Microbiol Infect.* 2018; 24: e1–e38.
- Brüggemann RJ, Donnelly JP, Aarnoutse RE et al. Therapeutic drug monitoring of voriconazole. *Ther Drug Monit*. 2008; 30: 403–411.
- Pascual A, Calandra T, Bolay S, Buclin T, Bille J, Marchetti O. Voriconazole tTherapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. *Clin Infect Dis.* 2008; 46: 201–211.
- Hamada Y, Seto Y, Yago K, Kuroyama M. Investigation and threshold of optimum blood concentration of voriconazole: a descriptive statistical meta-analysis. *J Infect Chemother*. 2012; 18: 501–507.
- Dolton MJ, Ray JE, Chen SC, Ng K, Pont LG, McLachlan AJ. 2012. Multicenter study of voriconazole pharmacokinetics and therapeutic drug monitoring. *Antimicrob Agents Chemother*. 2012; 56: 4793–4799.
- Neely M, Rushing T, Kovacs A, Jelliffe R, Hoffman J. Voriconazole pharmacokinetics and pharmacodynamics in children. *Clin Infect Dis*. 2010; 50: 27–36.
- Choi SH, Lee SY, Hwang JY et al. Importance of voriconazole therapeutic drug monitoring in pediatric cancer patients with invasive aspergillosis. *Pediatr Blood Cancer*. 2013; 60: 82–87.
- Soler-Palacin P, Frick MA, Martin-Nalda A et al. Voriconazole drug monitoring in the management of invasive fungal infection in immunocompromised children: a prospective study. J Antimicrob Chemother. 2012; 67: 700–706.

- Hu L, Dai TT, Zou L, Li TM, Ding XS, Yin T. Therapeutic drug monitoring of voriconazole in children: experience from a tertiary care center in China. *Antimicrob Agents Chemother*. 2018; 62: e00955–18. doi:10.1128/AAC.00955-18.
- Kang HM, Lee HJ, Cho EY et al. The clinical significance of voriconazole therapeutic drug monitoring in children with invasive fungal infections. *Pediatr Hematol Oncol.* 2015; 32: 557–567.
- Bruggemann RJ, van der Linden JW, Verweij PE, Burger DM, Warris A. Impact of therapeutic drug monitoring of voriconazole in a pediatric population. *Pediatr Infect Dis J.* 2011; 30: 533–534.
- Walsh TJ, Driscoll T, Milligan PA et al. Pharmacokinetics, safety, and tolerability of voriconazole in immunocompromised children. *Antimicrob Agents Chemother.* 2010; 54: 4116–4123.
- Friberg LE, Ravva P, Karlsson MO, Liu P. Integrated population pharmacokinetic analysis of voriconazole in children, adolescents, and adults. *Antimicrob Agents Chemother*. 2012; 56: 3032–3042.
- Walsh TJ, Karlsson MO, Driscoll T et al. Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration. *AntimicrobAgents Chemother*. 2004; 48: 2166–2172.
- 16. Groll AH, Castagnola E, Cesaro S et al. Fourth European Conference on Infections in L, Infectious Diseases Working Party of the European Group for Blood Marrow T, Infectious Diseases Group of the European Organisation for R, Treatment of C, International Immunocompromised Host S, European Leukaemia N. Fourth European Conference on Infections in Leukaemia (ECIL-4): guidelines for diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or allogeneic haemopoietic stem-cell transplantation. *Lancet Oncol.* 2014; 15: e327–340.
- Luong ML, Al-Dabbagh M, Groll AH et al. Utility of voriconazole therapeutic drug monitoring: a meta-analysis. J Antimicrob Chemother. 2016; 71: 1786– 1799.
- Matsumoto K, Ikawa K, Abematsu K et al. Correlation between voriconazole trough plasma concentration and hepatotoxicity in patients with different CYP2C19 genotypes. *Int J Antimicrob Agents*. 2009; 34: 91–94.
- Suzuki Y, Tokimatsu I, Sato Y et al. Association of sustained high plasma trough concentration of voriconazole with the incidence of hepatotoxicity. *Clin Chim Acta*. 2013; 424: 119–122.
- Tan K, Brayshaw N, Tomaszewski K, Troke P, Wood N. Investigation of the potential relationships between plasma voriconazole concentrations and visual adverse events or liver function test abnormalities. *J Clin Pharmacol.* 2006; 46: 235–243.
- Bartelink IH, Wolfs T, Jonker M et al. Highly variable plasma concentrations of voriconazole in pediatric hematopoietic stem cell transplantation patients. *Antimicrob Agents Chemother*. 2013; 57: 235–240.
- 22. Gerin M, Mahlaoui N, Elie C et al. Therapeutic drug monitoring of voriconazole after intravenous administration in infants and children with primary immunodeficiency. *Ther Drug Monit*. 2011; 33: 464–466.
- Michael C, Bierbach U, Frenzel K et al. Determination of saliva trough levels for monitoring voriconazole therapy in immunocompromised children and adults. *Ther Drug Monit.* 2010; 32: 194–199.
- Pieper S, Kolve H, Gumbinger HG, Goletz G, Wurthwein G, Groll AH. Monitoring of voriconazole plasma concentrations in immunocompromised paediatric patients. J Antimicrob Chemother. 2012; 67: 2717–2724.
- Karlsson MO, Lutsar I, Milligan PA. Population pharmacokinetic analysis of voriconazole plasma concentration data from pediatric studies. *Antimicrob Agents Chemother*. 2009; 53: 935–944.